All In Biotech

Drug Trial Radar · NCT06820723

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Ohio State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

Conditions

  • Depression
  • Anxiety
  • Major Depressive Disorder

Interventions

  • CYB003Drug

    synthetic, deuterated isotopomer of psilocin

  • PlaceboDrug

    Placebo orange drink solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in parameter estimate of regional brain activity measured by fMRI after one dose of CYB003 in participants with MDD and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo
  2. Changes in region-to-region connectivity measured by fMRI after one dose of CYB003 in patients with depression and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo
  3. Changes in event related potentials (ERP) after one dose of CYB003 in participants with MDD and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo.
  4. Changes in acoustic startle electromyographic (EMG) response after one dose of CYB003 in patients with depression and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ohio State University Department of Psychiatry

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.